logo
Plus   Neg
Share
Email

Roche: ENSPRYNG Approved In Japan For Treatment Of Neuromyelitis Optica Spectrum Disorder

Roche (RHHBY) announced the Japan's Ministry of Health, Labour and Welfare has approved ENSPRYNG for the prevention of relapses of neuromyelitis optica spectrum disorder. The company noted that ENSPRYNG is Japan's first and only approved therapy for both adults and children with neuromyelitis optica spectrum disorder.

Designed by Chugai Pharmaceutical Co., a member of the Roche group., ENSPRYNG is a humanised monoclonal antibody that targets the IL-6 receptor, believed to play a key role in the inflammation that occurs in people with neuromyelitis optica spectrum disorder.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT